Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Müschen M.

Nat Rev Cancer. 2018 Feb;18(2):103-116. doi: 10.1038/nrc.2017.111. Epub 2018 Jan 5. Review.

PMID:
29302068
2.

Portending death in germinal centers - when B cells know their time is up.

Wang L, Müschen M.

Cell Res. 2018 Jan;28(1):5-6. doi: 10.1038/cr.2017.151. Epub 2017 Dec 1.

PMID:
29192678
3.

Circadian clock cryptochrome proteins regulate autoimmunity.

Cao Q, Zhao X, Bai J, Gery S, Sun H, Lin DC, Chen Q, Chen Z, Mack L, Yang H, Deng R, Shi X, Chong LW, Cho H, Xie J, Li QZ, Müschen M, Atkins AR, Liddle C, Yu RT, Alkan S, Said JW, Zheng Y, Downes M, Evans RM, Koeffler HP.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12548-12553. doi: 10.1073/pnas.1619119114. Epub 2017 Nov 6.

PMID:
29109286
4.

Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.

Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D.

Nat Commun. 2017 Oct 17;8(1):978. doi: 10.1038/s41467-017-00880-2.

5.

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2017 Sep 8;8(38):64651. doi: 10.18632/oncotarget.20707. eCollection 2017 Sep 8.

6.

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.

Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, Baloglu E, Müschen M, Koeffler HP.

Leukemia. 2017 Sep 14. doi: 10.1038/leu.2017.281. [Epub ahead of print]

PMID:
28904384
7.

Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia.

Gugliotta G, Sudo M, Cao Q, Lin DC, Sun H, Takao S, Le Moigne R, Rolfe M, Gery S, Müschen M, Cavo M, Koeffler HP.

Neoplasia. 2017 Oct;19(10):750-761. doi: 10.1016/j.neo.2017.08.001. Epub 2017 Aug 29.

8.

B-cell identity as a metabolic barrier against malignant transformation.

Chan LN, Müschen M.

Exp Hematol. 2017 Sep;53:1-6. doi: 10.1016/j.exphem.2017.06.004. Epub 2017 Jun 24. Review.

PMID:
28655536
9.

Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases.

Rodríguez-Hernández G, Hauer J, Martín-Lorenzo A, Schäfer D, Bartenhagen C, García-Ramírez I, Auer F, González-Herrero I, Ruiz-Roca L, Gombert M, Okpanyi V, Fischer U, Chen C, Dugas M, Bhatia S, Linka RM, Garcia-Suquia M, Rascón-Trincado MV, Garcia-Sanchez A, Blanco O, García-Cenador MB, García-Criado FJ, Cobaleda C, Alonso-López D, De Las Rivas J, Müschen M, Vicente-Dueñas C, Sánchez-García I, Borkhardt A.

Cancer Res. 2017 Aug 15;77(16):4365-4377. doi: 10.1158/0008-5472.CAN-17-0701. Epub 2017 Jun 19.

PMID:
28630052
10.

mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA.

Mol Cancer Ther. 2017 Sep;16(9):1942-1953. doi: 10.1158/1535-7163.MCT-17-0024. Epub 2017 May 31.

PMID:
28566433
11.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

12.

Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.

Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, Weissman JS, Loh ML, Müschen M, Tasian SK, Bassik MC, Kampmann M, Pufall MA.

Blood. 2017 Jun 1;129(22):3000-3008. doi: 10.1182/blood-2017-02-766204. Epub 2017 Apr 19.

PMID:
28424165
13.

Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.

Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, Kornblau SM, Farrar MA.

Nat Immunol. 2017 Jun;18(6):694-704. doi: 10.1038/ni.3716. Epub 2017 Apr 3.

14.

BCL6 promotes glioma and serves as a therapeutic target.

Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Watkins A, Yang H, Ding LW, Jiang YY, Tyner JW, Ching J, Kovalik JP, Madan V, Chan SL, Müschen M, Breunig JJ, Lin DC, Koeffler HP.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3981-3986. doi: 10.1073/pnas.1609758114. Epub 2017 Mar 29.

15.

Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.

Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG.

Mol Syst Biol. 2017 Feb 15;13(2):914. doi: 10.15252/msb.20167159.

16.

Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.

Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N.

Cell Rep. 2017 Feb 14;18(7):1687-1698. doi: 10.1016/j.celrep.2017.01.057.

17.

Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13.

18.

Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL.

Schjerven H, Ayongaba EF, Aghajanirefah A, McLaughlin J, Cheng D, Geng H, Boyd JR, Eggesbø LM, Lindeman I, Heath JL, Park E, Witte ON, Smale ST, Frietze S, Müschen M.

J Exp Med. 2017 Mar 6;214(3):793-814. doi: 10.1084/jem.20160049. Epub 2017 Feb 11.

19.

Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.

Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA.

Blood. 2017 Mar 2;129(9):1155-1165. doi: 10.1182/blood-2016-06-722900. Epub 2016 Dec 28.

PMID:
28031181
20.

Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.

McCracken AN, McMonigle RJ, Tessier J, Fransson R, Perryman MS, Chen B, Keebaugh A, Selwan E, Barr SA, Kim SM, Roy SG, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider AJ, Clare S, Müschen M, Huwiler A, Kleinman MT, Hanessian S, Edinger AL.

Leukemia. 2017 Mar;31(3):669-677. doi: 10.1038/leu.2016.244. Epub 2016 Aug 30.

21.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

22.

Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.

Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, Peled A, Davis RE, Konopleva M, Burger JA.

Br J Haematol. 2016 Aug;174(3):425-36. doi: 10.1111/bjh.14075. Epub 2016 Apr 12.

23.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

24.

PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.

Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M.

Nat Med. 2016 Apr;22(4):379-87. doi: 10.1038/nm.4062. Epub 2016 Mar 14.

25.

Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.

Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.

Nature. 2016 Jun 2;534(7605):138. doi: 10.1038/nature16997. Epub 2016 Mar 9. No abstract available.

PMID:
26958840
26.

Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2016 Apr 5;7(14):18736-49. doi: 10.18632/oncotarget.7702. Erratum in: Oncotarget. 2017 Sep 8;8(38):64651.

27.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

28.

BCOR regulates myeloid cell proliferation and differentiation.

Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP.

Leukemia. 2016 May;30(5):1155-65. doi: 10.1038/leu.2016.2. Epub 2016 Feb 5.

29.

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.

Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA.

Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9. Epub 2016 Feb 5.

30.

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M.

Cell Rep. 2015 Dec 29;13(12):2715-27. doi: 10.1016/j.celrep.2015.12.003. Epub 2015 Dec 17.

31.

Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.

Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S.

Leukemia. 2016 Jun;30(6):1436-40. doi: 10.1038/leu.2015.331. Epub 2015 Dec 7. No abstract available.

32.

Infection and the Perils of B-cell Activation.

Greaves M, Müschen M.

Cancer Discov. 2015 Dec;5(12):1244-6. doi: 10.1158/2159-8290.CD-15-1243.

33.

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL.

Blood. 2015 Nov 5;126(19):2202-12. doi: 10.1182/blood-2015-04-639138. Epub 2015 Aug 31.

34.

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.

Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S.

Blood. 2015 Oct 8;126(15):1813-22. doi: 10.1182/blood-2015-06-651505. Epub 2015 Jul 28.

35.

Infectious origins of childhood leukemia.

Swaminathan S, Müschen M.

Oncotarget. 2015 Jul 10;6(19):16798-9. No abstract available.

36.

Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.

Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M.

Cancer Cell. 2015 Jul 13;28(1):114-28. doi: 10.1016/j.ccell.2015.05.008. Epub 2015 Jun 11.

37.

Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia.

Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M.

Nat Immunol. 2015 Jul;16(7):766-774. doi: 10.1038/ni.3160. Epub 2015 May 18.

38.

Ph+ ALL: drawing strength from a benign past.

Müschen M.

Blood. 2015 May 7;125(19):2879-80. doi: 10.1182/blood-2015-03-632174.

39.

HSP90 inhibitors decrease AID levels and activity in mice and in human cells.

Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM.

Eur J Immunol. 2015 Aug;45(8):2365-76. doi: 10.1002/eji.201545462. Epub 2015 May 18.

40.

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.

Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW.

J Hematol Oncol. 2015 Apr 22;8:39. doi: 10.1186/s13045-015-0132-6.

41.

Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Müschen M.

Blood. 2015 Jun 11;125(24):3688-93. doi: 10.1182/blood-2015-01-567842. Epub 2015 Apr 15. Review.

42.

Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.

Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.

Nature. 2015 May 21;521(7552):357-61. doi: 10.1038/nature14231. Epub 2015 Mar 23. Erratum in: Nature. 2016 Jun 2;534(7605):138.

43.

Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.

Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M.

Cancer Cell. 2015 Mar 9;27(3):409-25. doi: 10.1016/j.ccell.2015.02.003.

44.

Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.

Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M.

Nat Commun. 2015 Mar 10;6:6471. doi: 10.1038/ncomms7471.

45.

Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin.

Lu Z, Lieber MR, Tsai AG, Pardo CE, Müschen M, Kladde MP, Hsieh CL.

Mol Cell Biol. 2015 Apr;35(7):1209-22. doi: 10.1128/MCB.01085-14. Epub 2015 Jan 26.

46.

Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.

Buchner M, Swaminathan S, Chen Z, Müschen M.

Immunol Rev. 2015 Jan;263(1):192-209. doi: 10.1111/imr.12235. Review.

PMID:
25510278
47.

Follicular lymphoma: too many reminders for a memory B cell.

Swaminathan S, Müschen M.

J Clin Invest. 2014 Dec;124(12):5095-8. doi: 10.1172/JCI79189. Epub 2014 Nov 10.

48.

Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.

Fontanari Krause LM, Japp AS, Krause A, Mooster J, Chopra M, Müschen M, Bohlander SK.

Sci Rep. 2014 Oct 9;4:6565. doi: 10.1038/srep06565.

49.

Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.

Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M.

Proc Natl Acad Sci U S A. 2014 May 27;111(21):E2219-28. doi: 10.1073/pnas.1400958111. Epub 2014 May 12.

50.

Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Buchner M, Müschen M.

Curr Opin Hematol. 2014 Jul;21(4):341-9. doi: 10.1097/MOH.0000000000000048. Review.

Supplemental Content

Loading ...
Support Center